Hematology and Cell Therapy and Foundation for Applied Medical Research, Clínica Universidad de Navarra, University of Navarra, Spain.
J Mol Cell Cardiol. 2013 Sep;62:43-50. doi: 10.1016/j.yjmcc.2013.04.022. Epub 2013 Apr 30.
The possibility to induce pluripotency in somatic cells or, even further, to induce cell transdifferentiation through the forced expression of reprogramming factors has offered new, attractive options for cardiovascular regenerative medicine. In fact, recent discoveries have demonstrated that induced pluripotent stem (iPS) cells can be differentiated into cardiomyocytes, suggesting that iPS cells have the potential to significantly advance future cardiac regenerative therapies. Herein, we provide an overview of the characteristics and differentiation potential associated with iPS cells. In addition, we discuss current methods for inducing their specification towards a cardiovascular phenotype as well as in vivo evidence supporting the therapeutic benefit of iPS-derived cardiac cells. Finally, we describe recent findings regarding the use of iPS-derived cells for modeling several genetic cardiac disorders, which have indicated that these pluripotent cells represent an ideal tool for drug testing and might contribute to the development of future personalized regenerative cell therapies.
体细胞多能性的诱导，甚至更进一步地，通过重编程因子的强制表达诱导细胞转分化，为心血管再生医学提供了新的、有吸引力的选择。事实上，最近的发现表明诱导多能干细胞（iPS 细胞）可分化为心肌细胞，这表明 iPS 细胞有可能显著推进未来的心脏再生疗法。本文概述了 iPS 细胞的特征和分化潜能。此外，我们还讨论了目前诱导其向心血管表型特化的方法，以及支持 iPS 细胞来源的心脏细胞治疗益处的体内证据。最后，我们描述了最近关于使用 iPS 细胞衍生细胞来模拟几种遗传心脏疾病的发现，这些发现表明这些多能细胞是药物测试的理想工具，并可能有助于未来个性化再生细胞疗法的发展。
